MET30 Antibody

What is MET30 and why is it important in cellular biology?

MET30 is an F-box protein that functions as a critical component of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex in Saccharomyces cerevisiae (baker's yeast). As a subunit of the SCF^Met30 E3 ubiquitin ligase complex, MET30 plays essential roles in protein degradation pathways that regulate multiple cellular processes. MET30 was originally identified in screens for mutants defective in transcriptional repression of the MET25 gene, indicating its role in methionine-mediated transcriptional regulation .

The importance of MET30 is underscored by genetic studies demonstrating it is an essential gene, as disruption of MET30 results in lethality . The protein contains characteristic F-box and WD40 repeat domains that enable it to interact with both the SCF complex (through the F-box domain) and with specific substrate proteins targeted for ubiquitination and subsequent degradation (via the WD40 repeats).

How do MET30 antibodies differ from antibodies against the MET receptor tyrosine kinase?

This is a critical distinction that often causes confusion in the research community. MET30 antibodies target the yeast F-box protein MET30, while antibodies against the MET receptor tyrosine kinase (such as anti-MET antibody 5D5 or 107_A07) recognize the human receptor tyrosine kinase encoded by the MET proto-oncogene . These are entirely different proteins with distinct functions:

When ordering or citing these antibodies, researchers must be careful to specify the exact target to avoid experimental confusion .

What are the common applications for MET30 antibodies in yeast research?

MET30 antibodies serve as valuable tools for investigating ubiquitin-dependent proteolysis pathways in yeast. Common applications include:

• Western blotting to detect MET30 protein levels or post-translational modifications

• Immunoprecipitation to study protein-protein interactions involving MET30

• Chromatin immunoprecipitation (ChIP) to investigate potential associations with chromatin

• Immunofluorescence microscopy to examine subcellular localization

• Protein degradation assays to monitor SCF^Met30-mediated proteolysis

These antibodies are particularly valuable for studying cell cycle regulation, as MET30 has been implicated in the degradation of the Cdk-inhibitory kinase Swe1 . They are also useful for investigating heavy metal response mechanisms, as SCF^Met30 plays a critical role in the cellular response to toxic environmental heavy metals .

How should researchers validate a new MET30 antibody before experimental use?

Proper validation of MET30 antibodies is essential for reliable experimental results. A comprehensive validation protocol should include:

• Specificity testing: Compare antibody reactivity in wild-type versus MET30-deletion strains (using a conditional MET30 mutant since complete deletion is lethal). The signal should be absent or significantly reduced in the deletion strain .

• Western blot validation: Confirm a single band of appropriate molecular weight (~80 kDa for full-length MET30). Multiple bands may indicate degradation or cross-reactivity.

• Immunoprecipitation efficiency: Assess the antibody's ability to immunoprecipitate native MET30 protein, confirming with mass spectrometry if possible.

• Functionality testing: Verify that the antibody can detect changes in MET30 levels under conditions known to affect the protein (e.g., different nutrient conditions, cell cycle stages).

• Cross-reactivity assessment: Test for potential cross-reactivity with other F-box proteins, particularly closely related ones in the yeast proteome.

For polyclonal antibodies like the Rabbit anti-Saccharomyces cerevisiae MET30 Polyclonal Antibody, batch-to-batch variation should be evaluated by comparing new lots to previously validated lots .

What are the optimal conditions for using MET30 antibodies in Western blot applications?

Successful Western blot detection of MET30 requires careful optimization of several parameters:

It's critical to include appropriate controls, such as lysates from strains with altered MET30 expression levels and molecular weight markers .

How can researchers effectively use MET30 antibodies to study protein-protein interactions?

MET30 antibodies are valuable tools for investigating the protein interaction network of this F-box protein. Several approaches can be employed:

• Co-immunoprecipitation (Co-IP): The MET30 antibody can be used to pull down MET30 along with associated proteins. This approach has successfully identified interactions between MET30 and other SCF components like Cdc53 and Skp1 .

  • Protocol optimization: Pre-clear lysates thoroughly and use gentle wash conditions to preserve transient interactions.

  • Crosslinking: Consider mild crosslinking for capturing transient interactions.

  • Controls: Include non-specific IgG and lysates from strains lacking MET30 binding partners.

• Proximity labeling coupled with immunoprecipitation: Combining techniques like BioID with MET30 antibodies can identify proximal proteins in living cells.

• Two-hybrid verification: The two-hybrid interaction demonstrated between Met30 and Met4 (the transcriptional activator of MET25) can be further analyzed using MET30 antibodies to confirm physical interaction in vivo .

• Pull-down assays: GST-MET30 pull-down experiments have successfully demonstrated interactions with the Cdk-inhibitory kinase Swe1, which can be further characterized using MET30 antibodies .

When analyzing results, it's important to consider that some interactions may be transient or condition-dependent, such as those occurring only during specific cell cycle phases or under particular stress conditions.

How can MET30 antibodies be used to investigate the role of SCF^Met30 in cell cycle regulation?

MET30 antibodies provide powerful tools for dissecting the complex role of SCF^Met30 in cell cycle control, particularly regarding the Swe1 kinase. Advanced experimental approaches include:

• Synchronized cell studies: Use MET30 antibodies to track SCF^Met30 complex formation throughout the cell cycle in synchronized yeast cultures. This approach can reveal temporal regulation of the ubiquitin ligase activity.

• Phosphorylation-specific detection: Investigate how MET30 phosphorylation status affects its function by using phospho-specific antibodies or by performing phosphatase treatments prior to immunoblotting with standard MET30 antibodies.

• Substrate stabilization analysis: In temperature-sensitive met30 mutants, substrates like Swe1 become stabilized, resulting in characteristic elongated bud phenotypes due to delayed Clb1-4/Cdc28 kinase activation . MET30 antibodies can be used to correlate MET30 protein levels or modifications with substrate stabilization under various conditions.

• Genetic interaction verification: MET30 antibodies can help confirm the physical basis of genetic interactions, such as those observed between MET30 and CDC34, CDC53, and SKP1 . For example, immunoprecipitation with MET30 antibodies followed by immunoblotting for these interaction partners can reveal how mutations affect complex formation.

Research has demonstrated that met30-6 mutants display cell cycle phenotypes including unbudded cells with either G1 or G2/M DNA content, with a subset showing elongated buds characteristic of delayed Clb1-4/Cdc28 kinase activation. This phenotype becomes more pronounced in met30-6 mih1::LEU2 double mutants but is suppressed in met30-6 mih1::LEU2 swe1::URA3 triple mutants, indicating that Swe1 is a likely target of SCF^Met30 .

What are the technical challenges in detecting endogenous MET30 and how can they be overcome?

Detecting endogenous MET30 presents several technical challenges for researchers:

• Low abundance: As a regulatory protein, MET30 is typically expressed at relatively low levels, making detection difficult.

  Solution: Implement signal amplification methods such as using highly sensitive ECL substrates or consider protein concentration techniques prior to immunoblotting.

• Protein instability: F-box proteins often have short half-lives due to autoubiquitination.

  Solution: Include proteasome inhibitors (MG132 for mammalian cells or MG262 for yeast) in lysis buffers, and perform all sample handling at 4°C with freshly prepared samples.

• Antibody specificity: Cross-reactivity with other F-box proteins can complicate interpretation.

  Solution: Validate antibody specificity using temperature-sensitive met30 mutant strains as negative controls, and consider using epitope-tagged MET30 expressed under its endogenous promoter for confirmation .

• Post-translational modifications: Modifications can affect antibody recognition.

  Solution: Use multiple antibodies targeting different epitopes or employ denaturing conditions that may eliminate conformation-dependent epitope masking.

• Background noise: High background can obscure specific signals.

  Solution: Optimize blocking conditions (consider protein-free blockers) and increase wash stringency using higher salt concentrations or mild detergents.

Advanced detection methods, such as Proximity Ligation Assay (PLA) or highly sensitive mass spectrometry approaches, can also be employed to detect endogenous MET30 when conventional immunoblotting proves challenging.

How do temperature-sensitive met30 mutants facilitate research, and what controls should be included when using antibodies with these strains?

Temperature-sensitive (ts) met30 mutants are invaluable tools for studying MET30 function as complete deletion of MET30 is lethal. These mutants were constructed through PCR-based mutagenesis, creating alleles like met30-6 that grow normally at permissive temperature (25°C) but display conditional lethality at restrictive temperature (37°C) .

Advantages of temperature-sensitive mutants:

• Allow acute inactivation of MET30 function by temperature shift

• Enable the study of direct consequences of MET30 loss before secondary effects emerge

• Facilitate genetic interaction studies through the creation of double mutants

• Provide a system to study substrate accumulation upon MET30 inactivation

Controls and considerations when using antibodies with ts mutants:

• Epitope validation: Confirm that the temperature-sensitive mutation doesn't affect the epitope recognized by the antibody. Compare antibody reactivity at permissive and restrictive temperatures in wild-type strains.

• Kinetic analysis: When shifting to restrictive temperature, include multiple time points to track the progression of MET30 inactivation and its consequences.

• Essential controls:

  • Wild-type strain at both temperatures

  • ts mutant at permissive temperature

  • Additional controls specific to the experimental question (e.g., double mutants)

• Specificity verification: Use multiple antibodies targeting different epitopes to ensure observed changes are due to the ts mutation rather than epitope masking.

• Rescue controls: Include controls where the ts phenotype is rescued by plasmid-borne wild-type MET30 or suppressed by overexpression of interacting proteins like CDC34 .

Research has demonstrated that the temperature sensitivity of met30-6 mutants can be suppressed by increased dosage of Cdc34 or Skp1, reinforcing the functional connection between these proteins in the SCF complex .

How do MET30 antibodies compare with antibodies against other F-box proteins in experimental applications?

When selecting antibodies for F-box protein research, understanding the comparative advantages and limitations is crucial:

MET30 antibodies are particularly valuable for studying the connections between metabolic regulation and cell cycle control, while CDC4 antibodies are often preferred for examining core cell cycle regulatory mechanisms .

When designing experiments involving multiple F-box proteins, consistency in antibody format (polyclonal vs. monoclonal) and detection methods can facilitate more direct comparisons between different pathways.

What emerging techniques are enhancing the utility of MET30 antibodies in current research?

Recent methodological advances are expanding the applications of MET30 antibodies:

• Proximity-dependent biotinylation: Techniques like BioID or TurboID fused to MET30 can identify transient interaction partners when combined with MET30 antibodies for verification.

• Super-resolution microscopy: Advanced imaging techniques coupled with highly specific MET30 antibodies enable precise subcellular localization studies beyond conventional microscopy limitations.

• Single-cell analysis: Combining flow cytometry with intracellular staining using MET30 antibodies allows correlation of MET30 levels with cell cycle position or stress response at the single-cell level.

• CRISPR-based approaches: MET30 antibodies are being used to validate CRISPR-edited strains expressing tagged versions of MET30, enabling new functional studies.

• Quantitative proteomics: Advanced mass spectrometry techniques combined with immunoprecipitation using MET30 antibodies allow precise quantification of interaction dynamics and post-translational modifications.

• Microfluidics applications: Continuous monitoring of MET30 levels in microfluidic-trapped single yeast cells using fluorescent antibodies provides insights into cell-to-cell variability and temporal dynamics.

These emerging approaches are particularly valuable for understanding how MET30 functions at the interface of multiple regulatory pathways, including its recently discovered role in heavy metal response mechanisms .

How does research on yeast MET30 inform understanding of its mammalian homologs, and what antibody considerations apply in comparative studies?

Yeast MET30 serves as an important model for understanding F-box protein function in higher eukaryotes. Sequence comparison reveals that MET30 is the closest budding yeast relative of Drosophila Slimb rather than Cdc4 as previously proposed . This evolutionary relationship extends to mammals, where β-TrCP (beta-transducin repeat containing protein) represents the functional counterpart.

Evolutionary relationships and functional conservation:

• MET30, Slimb, and β-TrCP share structural features including the F-box domain and WD40 repeats

• These proteins function in SCF ubiquitin ligase complexes that regulate critical cellular pathways

• While specific substrates may differ, the mechanism of substrate recognition through phosphodegrons is conserved

• Both yeast MET30 and mammalian β-TrCP have roles in cell cycle regulation and stress responses

Antibody considerations for comparative studies:

When designing experiments to investigate functional conservation between yeast MET30 and mammalian homologs like β-TrCP, researchers should consider:

• Epitope conservation: Epitopes recognized by MET30 antibodies may not be conserved in mammalian homologs, necessitating separate validated antibodies for each organism.

• Cross-reactivity testing: If conducting studies across species, extensive validation is required to ensure antibody specificity within each system. Some antibodies against human BTRC (β-TrCP) may cross-react with the yeast protein .

• Functional domain targeting: Antibodies targeting highly conserved functional domains may provide insights into evolutionary conservation but might lack specificity.

• Substrate recognition: For studying substrate interactions, consider that while the mechanism of phosphodegron recognition is conserved, specific substrates differ between species.

• Controls for heterologous expression: When expressing mammalian β-TrCP in yeast or vice versa, appropriate controls with species-specific antibodies are essential.

This comparative approach has proven valuable in understanding how the mechanisms of protein degradation and cell cycle control have evolved from yeast to humans, potentially informing therapeutic approaches targeting these pathways .

What are the most common problems when working with MET30 antibodies and how can they be resolved?

Researchers frequently encounter specific challenges when working with MET30 antibodies. Here are the most common issues and their solutions:

• Weak or absent signal in Western blots

  • Cause: Low MET30 abundance, protein degradation, or inefficient transfer

  • Solution: Increase protein loading (60-80 μg), add proteasome inhibitors to lysis buffer, optimize transfer conditions for high molecular weight proteins, and consider using PVDF membranes instead of nitrocellulose

• Multiple bands or unexpected molecular weight

  • Cause: Protein degradation, post-translational modifications, or antibody cross-reactivity

  • Solution: Use fresh samples with complete protease inhibitor cocktails, compare with positive controls using tagged MET30, and verify with a second antibody targeting a different epitope

• High background in immunofluorescence

  • Cause: Non-specific binding or autofluorescence

  • Solution: Increase blocking time (overnight at 4°C), use alternative blocking agents (5% BSA or commercial blockers), include 0.1% Triton X-100 in wash buffers, and optimize antibody dilution

• Unsuccessful immunoprecipitation

  • Cause: Epitope inaccessibility or antibody binding interference

  • Solution: Try different lysis conditions (adjust salt and detergent), use alternative antibodies, or consider epitope-tagged MET30 approaches with anti-tag antibodies

• Inconsistent results between experiments

  • Cause: Antibody batch variation or protocol inconsistencies

  • Solution: Maintain detailed records of antibody lots, standardize all protocol steps, and include consistent positive controls in each experiment

How can researchers distinguish between specific and non-specific signals when using MET30 antibodies?

Establishing signal specificity is critical for accurate data interpretation when using MET30 antibodies:

• Genetic controls: The gold standard approach is comparing signals between wild-type and met30 mutant strains. Since MET30 deletion is lethal, use temperature-sensitive mutants (like met30-6) shifted to restrictive temperature or strains with regulated MET30 expression (e.g., under the GAL1 promoter) .

• Competing peptide controls: Pre-incubate the antibody with the peptide used as immunogen before application to samples. Specific signals should disappear while non-specific binding remains.

• Multiple antibodies approach: Use two or more antibodies targeting different epitopes of MET30. True signals should be detected by all antibodies, while non-specific signals typically differ.

• Signal correlation with biological conditions: Verify that signal changes correlate with conditions known to affect MET30, such as cell cycle stages or nitrogen source availability.

• Molecular weight verification: MET30 should appear at approximately 80 kDa. Signals at dramatically different molecular weights likely represent non-specific binding unless they correspond to known isoforms or degradation products.

• Overexpression controls: Compare endogenous signals with samples overexpressing MET30. Specific signals should increase proportionally while non-specific bands remain unchanged.

• Antibody dilution series: Specific signals typically decrease proportionally with antibody dilution, while non-specific background may decrease non-linearly.

What quality control measures should be implemented for long-term reproducibility when working with MET30 antibodies?

Ensuring long-term reproducibility requires systematic quality control practices:

• Antibody validation documentation: Maintain detailed records for each antibody lot, including:

  • Validation experiments performed (Western blot, IP, IF)

  • Optimal working dilutions for each application

  • Observed banding patterns with molecular weight markers

  • Positive and negative control results

  • Batch-to-batch comparison data

• Reference sample banking: Create and maintain reference samples that can be used to validate new antibody lots or troubleshoot inconsistent results:

  • Flash-frozen yeast lysates from wild-type strains

  • Lysates from strains with MET30 under regulatable promoters

  • Purified recombinant MET30 protein (full-length or domains)

• Standardized protocols: Develop detailed standard operating procedures (SOPs) for:

  • Sample preparation (harvesting, lysis, storage)

  • Antibody handling and storage

  • Each application (Western blot, IP, IF)

  • Data analysis and interpretation

• Regular antibody performance monitoring: Implement scheduled quality checks:

  • Test antibody performance every 3-6 months

  • Monitor for changes in signal intensity or background

  • Compare current results with historical data

• Positive control inclusion: Always include well-characterized positive controls in experiments:

  • Strains expressing tagged MET30

  • Samples with known MET30 expression levels

  • Previously validated experimental conditions

• Laboratory information management: Use electronic lab notebooks or database systems to track:

  • Antibody lot numbers and purchase dates

  • Storage conditions and freeze-thaw cycles

  • Experimental conditions and results

  • Troubleshooting notes and optimization parameters

These quality control measures are particularly important for polyclonal antibodies like the Rabbit anti-Saccharomyces cerevisiae MET30 Polyclonal Antibody, where batch-to-batch variation can significantly impact experimental outcomes .